XSHG
603367
Market cap976mUSD
Oct 09, Last price
14.68CNY
1D
1.66%
1Q
7.31%
IPO
-20.52%
Name
Cisen Pharmaceutical Co Ltd
Chart & performance
P/E
15.78
P/S
1.93
EPS
0.93
Div yield, %
2.83%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-1.28%
Revenues
3.44b
-13.48%
Net income
421m
-17.22%
CFO
619m
+8.52%
Dividend
Sep 16, 20260.216 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cisen Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, manufacturing and distributing a diverse portfolio of chemical drug preparations and healthcare products to both domestic and international markets. Founded in 1998 and based in Jining, People's Republic of China, the company offers an extensive range of chemical drug solutions. These include medications for liver diseases, antitumor and supportive treatments, nutritional supplements, contrast agents, antibiotics, digestive system remedies, polypropylene ampoules, and topical preparations. Additionally, their product line encompasses sedation and anesthesia agents, cardiovascular drugs, treatments for cough and asthma, immunomodulators, and various infusion and therapeutic infusion products. The company officially changed its name to Cisen Pharmaceutical Co., Ltd. in 2011, having previously operated as Shandong Lukang Cisen Pharmaceutical Co., Ltd.
Key people
Yanzhen Han
Deputy General Manager
Liushan Hao
Deputy General Manager
Honghui Sun
Secretary of the Board · since 2017
Zhenxin Du
Chairman of the Board, General Manager
Headquarters & legal address
山东省济宁高新区同济科技工业园
济宁市, SD 272000
CN
济宁市, SD 272000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||